- American City Business Journals•3 days ago
Navidea Biopharmaceuticals Inc. and Cardinal Health Inc. have reached a settlement with Navidea's chief lender that clears the path to close an $80 million deal and pay off the lender next week – but also puts off the final decision on how much ultimately is owed . Navidea's fate is subject to a firm deadline in the settlement in Franklin County Common Pleas Court that was disclosed Thursday in a Securities and Exchange Commission filing. Cardinal must close on its purchase of North American rights to Navidea's cancer diagnostic aid Lymphoseek by March 10, or lender CRG can foreclose on its loan by selling off shares pledged as collateral.
- Business Wire•last month
Navidea Biopharmaceuticals, Inc. today announced that management will hold an audio webcast conference call on Tuesday, January 31, 2017 at 4:30 p.m. to provide investor update on status of ongoing corporate events.
- Business Wire•2 months ago
Navidea Biopharmaceuticals, Inc. today announced that management will present at an upcoming investor conference. An audio webcast of the presentation will be available live at the URL links noted below.
NAVB : Summary for Navidea Biopharmaceuticals, Inc - Yahoo Finance
Navidea Biopharmaceuticals, Inc (NAVB)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.46 - 0.51|
|52 Week Range||0.26 - 1.51|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|